Concord Biotech Ltd (CONCORDBIO) is currently trading at 1,330.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Concord Biotech Limited is a leading bio-pharma company focused on fermentation-based APIs for immunosuppressants and oncology. It operates across numerous global markets, including the US, Europe, and Japan. Recent developments include regulatory approvals from USFDA and EU-GMP, bolstering global market penetration and business continuity. Entry into cell and gene therapy through investment in Cellimmune Biotech highlights new growth avenues. The company faced challenges in Q2 FY26 due to delays with CDSCO approvals and geopolitical issues affecting sales in Europe and the Middle East, but expects these to be timing differences with no long-term impact. Despite temporary setbacks, Concord Biotech maintained robust gross profit margins, driven by enhanced operations and strategic investments, especially in the newly commissioned injectable facilities. Expansion efforts are underway in second-source markets. Concord Biotech's diversification strategy includes expanding into formulations and enhancing its CDMO business, positioning it for sustainable growth across global pharmaceutical markets.

Over the past 52 weeks, Concord Biotech Ltd has traded between a low of ₹1,100.00 and a high of ₹2,451.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Concord Biotech Ltd has a market capitalization of approximately 14,011.25. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Concord Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 42.96 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Concord Biotech Ltd (CONCORDBIO) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 14,011.25 Cr, Concord Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Concord Biotech Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Concord Biotech Ltd is 42.96. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Concord Biotech Ltd pays dividends with a current dividend yield of 0.65%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with Concord Biotech Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.